Avistone Biotechnology Co., Ltd.
Clinical trials sponsored by Avistone Biotechnology Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for rare lung cancer: targeted drug trial launches Results expected Nov 2026 (estimated)
- New cancer drug ANS014004 enters first human tests Results expected Apr 2027 (estimated)
-
New targeted drug shows promise for hard-to-treat lung cancer
Disease control OngoingThis study tests a new drug called PLB1004 in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors and how safe it is. About 139 adults who have already tried oth…
Phase 2 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill takes on hard-to-treat lung cancer in major trial
Disease control By invitation onlyThis study tests a new drug called PLB1004 against standard chemotherapy for people with advanced non-small-cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 327 adults with this cancer type will be randomly assigned to receive either PLB1004 or …
Phase 3 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer pill enters first human tests for advanced solid tumors
Disease control OngoingThis early-phase trial is testing an experimental oral drug called ANS014004 in 40 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, then expanding to see if the drug can shrink tumors. The m…
Phase 1 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC